Search results for "isoenzymes"

showing 10 items of 244 documents

Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.

2013

Globotriaosylceramide concentrations were assessed as potential predictors of change from baseline after 12 months by estimated glomerular filtration rate and left-ventricular mass index using pooled data from three randomized, placebo-controlled agalsidase alfa trials and open-label extensions of patients with Fabry disease.Males (aged 18 years or older) with Fabry disease received agalsidase alfa (0.2 mg/kg every other week for 12 months). A backward-elimination approach evaluated potential predictors (baseline estimated glomerular filtration rate and left-ventricular mass index; age at first dose; baseline and change from baseline at 12 months of globotriaosylceramide (urine, plasma); ur…

AdultMalemedicine.medical_specialtyHeart VentriclesUrologyGlobotriaosylceramideRenal functionUrinechemistry.chemical_compoundYoung Adultstomatognathic systemDouble-Blind MethodMedicineHumansRenal Insufficiency Chronicskin and connective tissue diseasesGenetics (clinical)Alpha-galactosidasebiologybusiness.industryTrihexosylceramidesvirus diseasesEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseasedigestive system diseasesRecombinant ProteinsIsoenzymesTreatment Outcomechemistryalpha-Galactosidasebiology.proteinDisease ProgressionBiomarker (medicine)Fabry Diseasesense organsbusinessBiomarkersKidney diseaseGlomerular Filtration RateGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct

Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.

2007

Aims Anderson–Fabry disease (AFD) is an uncommon X-linked disorder caused by deficient activity of the lysosomal enzyme α-galactosidase A. The Fabry Outcome Survey is a European database designed to monitor the long-term efficacy and safety of enzyme replacement therapy (ERT) with agalsidase alfa. The aim of this study was to determine the prevalence and characteristics of cardiac disease in AFD patients. Methods and results Clinical and laboratory data were available in 714 patients from 11 countries (mean age 35 ± 17 years, 369 women, 336 treated). The prevalence of angina was 23 vs. 22%; palpitations and arrhythmias 27 vs. 26%; exertional dyspnoea 23 vs. 23%; and syncope 2 vs. 4%, in wom…

AdultMalemedicine.medical_specialtyHeart diseaseHeart DiseasesCardiomyopathyLeft ventricular hypertrophySyncopeAnginaRisk FactorsInternal medicinemedicinePalpitationsPrevalenceHumansVascular diseasebusiness.industryEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseRecombinant ProteinsSurgeryEuropeIsoenzymesDyspneaTreatment OutcomeEchocardiographyalpha-GalactosidaseFabry DiseaseFemaleHypertrophy Left Ventricularmedicine.symptomCardiology and Cardiovascular MedicinebusinessGlomerular Filtration RateEuropean heart journal
researchProduct

Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.

1993

1. We have investigated the role of cyclic nucleotide phosphodiesterase IV (PDE IV) in the relaxation of human bronchus and guinea-pig trachea in vitro and in guinea-pigs in vivo. 2. Functional studies showed that the selective PDE IV inhibitors, rolipram and denbufylline, relaxed human and guinea-pig preparations in vitro. 3. Two clinically used xanthine non-selective PDE inhibitors, theophylline and pentoxifylline, were also effective in these preparations, but were much less potent than the selective agents used. 4. The rank order of potency for the four PDE inhibitors in both species was similar. 5. Biochemical studies indicated that PDE IV was the major PDE isoform present in the human…

AdultMalemedicine.medical_specialtyPhosphodiesterase InhibitorsGuinea PigsBiologyIn Vitro TechniquesPentoxifyllinechemistry.chemical_compoundTheophyllineIn vivoInternal medicinemedicineAnimalsHumansTheophyllineheterocyclic compoundsPentoxifyllineRolipramAgedPharmacologyCyclic nucleotide phosphodiesterasePhosphoric Diester HydrolasesIsoproterenolMiddle AgedXanthinemusculoskeletal systemAsthmaPyrrolidinonesBronchodilator AgentsCyclic Nucleotide Phosphodiesterases Type 4IsoenzymesBronchodilatationenzymes and coenzymes (carbohydrates)Disease Models AnimalEndocrinologychemistryEnzyme inhibitor3'5'-Cyclic-AMP PhosphodiesterasesXanthinesbiology.proteinFemalesense organsRoliprammedicine.drugcirculatory and respiratory physiologyResearch Article
researchProduct

Enzyme Replacement Therapy Stabilized White Matter Lesion Progression in Fabry Disease

2014

<b><i>Background:</i></b> The central nervous system manifestations in Fabry disease (FD) include progressive white matter lesions (WMLs) and stroke. Due to progressive microvascular involvement, men and women with FD over 35 years of age develop WMLs. Moreover, the prevalence of stroke has been estimated to be 12 times higher in FD compared with the general population. Enzyme replacement therapy (ERT) is available and has shown beneficial effects on renal, cardiac, and peripheral nerve function in FD, but the ERT effect on the progression of WMLs, or the reduction in cerebrovascular events, remains unknown. <b><i>Methods:</i></b> The WML burd…

AdultMalemedicine.medical_specialtyPopulationPlaceboLeft ventricular hypertrophyYoung AdultLeukoencephalopathiesInternal medicinemedicineHumansEnzyme Replacement TherapyeducationStrokeAgededucation.field_of_studyVascular diseasebusiness.industryBrainEnzyme replacement therapyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingWhite MatterFabry diseaseHyperintensitySurgeryIsoenzymesNeurologyalpha-GalactosidaseDisease ProgressionCardiologyFabry DiseaseFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessCerebrovascular Diseases
researchProduct

Relationship between circulating E-selectin, DD genotype of angiotensin-converting-enzyme, and cardiovascular damage in central obese subjects

2003

Fifty-six young central obese patients were investigated to evaluate relationships between soluble E-selectin (sE-S), angiotensin-converting enzyme (ACE) gene polymorphism, left ventricular function and structure, and carotid morphology by determination of sE-S and ACE genotypes. Our results indicated that central obese subjects with concomitant higher levels of sE-S and ACE DD genotype may be characterized by early cardiovascular alterations and then considered a particular subset of subjects at higher risk of cardiovascular disease.

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internaangiotensin-converting-enzyme cardiovascular damageGenotypeArteriosclerosisEndocrinology Diabetes and MetabolismBlood PressureDiseasecentral obese subjectsPeptidyl-Dipeptidase ABody Mass Indexcirculating E-selectin genotype; angiotensin-converting-enzyme cardiovascular damage; central obese subjectsEndocrinologyRisk FactorsInternal medicineGenotypeE-selectinmedicineHumansInsulinObesityAllelesbiologyVentricular functionHemodynamicsHeartAngiotensin-converting enzymeGlucose Tolerance TestSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheIsoenzymesCarotid ArteriesEndocrinologyCardiovascular DiseasesEchocardiographyConcomitantbiology.proteinRegression AnalysisFemaleObese subjectsGene polymorphismE-Selectincirculating E-selectin genotypeMetabolism
researchProduct

Advantages of immediate two-dimensional echocardiography in patients with acute cardiac ischemic events

1995

Abstract We hypothesized that the assessment of kinetic alterations on two dimensional echocardiogram (2DE) would provide greater diagnostic information than clinical symptoms and ECG changes only. The study was aimed to determine sensitivity of 2DE in patients with cardiac ischemic events and to improve the indications to thrombolysis. Three-hundred ninety-one patients (87 F; 304 M) hospitalized for suspected acute myocardial infarction (AMI), first episode, within 4 h from the onset of symptoms, suitable for thrombolysis Killip class I–II and with unstable angina (UA), were admitted in the study. Patients had to show ECG changes and alterations of segmentary motion on 2DE performed at ent…

AdultMalemedicine.medical_specialtySystolemedicine.medical_treatmentMyocardial InfarctionMyocardial IschemiaIschemiaInfarctionSensitivity and SpecificityVentricular Function LeftElectrocardiographyFibrinolytic AgentsInternal medicinemedicineHumansThrombolytic TherapyAngina Unstablecardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryCoronary Artery BypassCreatine KinaseAgedKillip classAged 80 and overFirst episodeHeparinVascular diseaseUnstable anginabusiness.industryThrombolysisMiddle Agedmedicine.diseaseIsoenzymesSurvival RateEchocardiographyVentricular Function RightCardiologyFemaleCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data

2009

Summary Background We analysed 5-year treatment with agalsidase alfa enzyme replacement therapy in patients with Fabry's disease who were enrolled in the Fabry Outcome Survey observational database (FOS). Methods Baseline and 5-year data were available for up to 181 adults (126 men) in FOS. Serial data for cardiac mass and function, renal function, pain, and quality of life were assessed. Safety and sensitivity analyses were done in patients with baseline and at least one relevant follow-up measurement during the 5 years (n=555 and n=475, respectively). Findings In patients with baseline cardiac hypertrophy, treatment resulted in a sustained reduction in left ventricular mass (LVM) index af…

AdultMalemedicine.medical_specialtyUrologyRenal functionKidney Function TestsMuscle hypertrophyQuality of lifeSurveys and QuestionnairesEpidemiologymedicineHumansRegistriesPain MeasurementVascular diseasebusiness.industryGeneral MedicineEnzyme replacement therapymedicine.diseaseFabry's diseaseFabry diseaseRecombinant ProteinsSurgeryIsoenzymesTreatment Outcomealpha-GalactosidaseHeart Function TestsQuality of LifeFabry DiseaseFemalebusinessThe Lancet
researchProduct

Islet autoantibodies in Latvian subjects with non-insulin-dependent diabetes mellitus: slow-onset type 1 diabetes or polyendocrine autoimmunity?

2006

In Latvia diabetes mellitus is diagnosed using the WHO's clinical criteria; assays for the detection of autoantibodies are not available, and hence slowly progressive autoimmune diabetes is likely to be missed. Autoantibodies against glutamic acid decarboxylase (GAD65) and protein tyrosine phosphatase (IA-2) among patients with clinically diagnosed NIDDM identify group of patients with slow-onset type 1 diabetes or LADA. The aim of this study was to estimate the risk of polyendocrine autoimmunity among clinically diagnosed NIDDM patients from Latvia. One hundred NIDDM patients and 100 healthy controls were tested for GAD65 and IA-2 autoantibodies as well as 21-hydroxylase (21-OH) and tissue…

AdultMalemedicine.medical_specialtyendocrine system diseasesAdolescentTissue transglutaminasemedicine.medical_treatmentOverweightmedicine.disease_causeAutoantigensGeneral Biochemistry Genetics and Molecular BiologyAutoimmunityDiagnosis DifferentialHistory and Philosophy of ScienceInternal medicineDiabetes mellitusmedicineHumansReceptor-Like Protein Tyrosine Phosphatases Class 8ChildPolyendocrinopathies AutoimmuneAutoantibodiesProtein Tyrosine Phosphatase Non-Receptor Type 1Type 1 diabetesbiologybusiness.industryGlutamate DecarboxylaseGeneral NeuroscienceInsulinAutoantibodynutritional and metabolic diseasesMembrane Proteinsmedicine.diseaseLatviaIsoenzymesEndocrinologyDiabetes Mellitus Type 1Child Preschoolbiology.proteinFemalemedicine.symptomProtein Tyrosine PhosphatasesbusinessBody mass indexBiomarkersAnnals of the New York Academy of Sciences
researchProduct

Risk factors for clinical stress fractures in male military recruits: A prospective cohort study

2004

This prospective study was aimed at evaluating risk factors for symptomatic stress fractures among 179 Finnish male military recruits, aged 18 to 20 years. The subjects were studied in the very beginning of the military service of 6 to 12 months in summer. Bone mineral content (BMC) and density (BMD) were measured by dual energy X-ray absorptiometry (DXA) at the lumbar spine and at the hip and heel ultrasound investigation was performed. Blood was sampled for determination of serum total and free testosterone, total and free estradiol, sex hormone-binding globulin (SHBG), procollagen type I N propeptide, total and carboxylated osteocalcin, tartrate-resistant acid phosphatase 5b, 25-hydroxyv…

AdultMalemusculoskeletal diseasesmedicine.medical_specialtyHistologyAdolescentFractures StressBone densityPhysiologyEndocrinology Diabetes and MetabolismAcid PhosphataseOsteocalcinParathyroid hormoneCollagen Type IBone remodelingSex hormone-binding globulinN-terminal telopeptideBone DensityRisk FactorsSex Hormone-Binding GlobulinInternal medicinemedicineHumansTestosteroneProspective StudiesVitamin DProspective cohort studyFemoral neckPolymorphism GeneticStress fracturesEstradiolbiologyTartrate-Resistant Acid Phosphatasebusiness.industrymedicine.diseaseIsoenzymesMilitary Personnelmedicine.anatomical_structureEndocrinologyReceptors EstrogenParathyroid HormoneReceptors Androgenbiology.proteinbusinessBone
researchProduct

Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.

2003

Summary: Fabry disease is an X-linked glycosphingolipid storage disorder caused by a deficiency of α-galactosidase A. Affected patients experience debilitating neuropathic pain and have premature mortality due to renal failure, cardiovascular disease or cerebrovascular complications. The disease may be X-linked dominant, since most females heterozygous for Fabry disease are affected clinically. We evaluated the safety, efficacy and pharmacokinetics of agalsidase alfa (Replagal) administered intravenously to female patients with Fabry disease in an open-label, single-centre study. Fifteen severely affected patients received agalsidase alfa at 0.2 mg/kg every other week for up to 55 weeks. Ag…

Adultmedicine.medical_specialtyHeterozygoteAdolescentArthritisRenal functionKidneyGastroenterologyAntibodiesArthritis RheumatoidElectrocardiographyPharmacokineticsInternal medicineGeneticsmedicineHumansGenetics (clinical)Vascular diseasebusiness.industryTrihexosylceramidesEnzyme replacement therapymedicine.diseaseFabry diseaseRecombinant ProteinsSurgeryClinical trialIsoenzymesEchocardiographyalpha-GalactosidaseNeuropathic painMutationFabry DiseaseFemalebusinessJournal of inherited metabolic disease
researchProduct